Wed, 07 Dec 2022 08:30:00 +0100

Correction: Interim Report 220701-220930

Press Release 7 December, 2022

In November 2022, the company discovered a misstatement of grants in the Q3 report, as the government grants received are reported as other operating income. The terms of the government grants require the grants to fund the company's development projects and are recorded as advance government grants on the balance sheet. The net amount does not affect the cash flow of the enterprise but is a transfer from the income statement to the balance sheet.

The impact on the Parent Company and the Group for Q3, 2022 will be as follows:

For more information please contact:

Ina Laura Perkins, CEO

Phone: +46(0)70 406 49 21 


Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Phone: +46 11 32 30 732, email:

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart® TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation. A unique concept in the medical technology world.

Correction: Interim Report 220701-220930 (PDF)
Realheart Interim Report Q3 2022 ENG 221207 (PDF)